Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control

Type 2 diabetes (T2D) is one of the most common chronic metabolic disorders in adulthood worldwide, whose pathophysiology includes an abnormal immune response accompanied by cytokine dysregulation and inflammation. As the T2D-related inflammation and its progression were associated with the balance...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2021, Vol.2021, p.7297419-12
Main Authors: Velikova, Tsvetelina V., Kabakchieva, Plamena P., Assyov, Yavor S., Georgiev, Tsvetoslav А.
Format: Article
Language:English
Subjects:
Antibodies
Apoptosis
Beta cells
Cardiovascular disease
Care and treatment
Chemokines
Clinical trials
Clinical Trials as Topic
Cytokines
Cytokines - metabolism
Development and progression
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Disease control
Drug targeting
Drug therapy
Genetic aspects
Glucose
Health aspects
Humans
Hyperglycemia
Immune response
Immunosuppressive agents
Inflammation
Inflammation Mediators - metabolism
Insulin
Insulin resistance
Insulin secretion
Interleukin 1
Interleukin 17
Interleukin 23
Lupus
Lymphocytes
Metabolic disorders
Metabolism
Models, Biological
Molecular modelling
Obesity
Pathogenesis
Pathophysiology
Patient outcomes
Pharmacology, Experimental
Physiological aspects
Proteins
Review
Rheumatic diseases
Rheumatoid arthritis
Risk factors
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Type 2 diabetes (T2D) is one of the most common chronic metabolic disorders in adulthood worldwide, whose pathophysiology includes an abnormal immune response accompanied by cytokine dysregulation and inflammation. As the T2D-related inflammation and its progression were associated with the balance between pro and anti-inflammatory cytokines, anticytokine treatments might represent an additional therapeutic option for T2D patients. This review focuses on existing evidence for antihyperglycemic properties of disease-modifying antirheumatic drugs (DMARDs) and anticytokine agents (anti-TNF-α, anti-interleukin-(IL-) 6, -IL-1, -IL-17, -IL-23, etc.). Emphasis is placed on their molecular mechanisms and on the biological rationale for clinical use. Finally, we briefly summarize the results from experimental model studies and promising clinical trials about the potential of anticytokine therapies in T2D, discussing the effects of these drugs on systemic and islet inflammation, beta-cell function, insulin secretion, and insulin sensitivity.
ISSN:2314-6133
2314-6141
DOI:10.1155/2021/7297419